Takeda Announces Positive Phase 3 Results for Zasocitinib

Takeda Canada is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis. In the LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. The study was conducted across eight countries and enrolled 606 participants, including 73 patients across 18 sites in Canada.